2026-01-27 02:10Summary of Key Points from Conference Call Records Company: Junshi Biosciences (君实生物) Industry: Biopharmaceuticals Core Insights and Arguments - Discovery of VV116: The Wuhan Institute of Virology published findings on January 26, indicating that VV116 exhibits high inhibitory activity against the Nipah virus, including strains NiV-M and NiV-B [1] - Mechanism of Action: VV116, a novel oral nucleoside antiviral drug, demonstrated significant suppression of the Nipah virus in both its active form and its metabolites [1] - Efficacy in Animal Models: In a lethal dose infection model using golden hamsters, VV116 administered at a dose of 400 mg/kg increased the survival rate of the experimental animals to 66.7% and significantly reduced viral loads in target organs such as the lungs, spleen, and brain [1] Additional Important Information - Broad Pipeline: Junshi Biosciences has a wide-ranging portfolio that includes antiviral drugs, small nucleic acids, bispecific antibodies, antibody-drug conjugates (ADC), cytokines, and vaccines [1] - Underestimation of Company Value: The company is considered severely undervalued, with projections indicating strong performance in 2025. This could lead to a positive feedback loop for the company [2] - Accelerated Innovation Pipeline: Junshi currently has over 50 products in development, with 5 products in Phase III clinical trials or registration stages (IL-17, subcutaneous Trelagliptin, PI3K, Claudin18.2 ADC, BTLA) and 5 products in Phase II clinical trials, nearing or entering Proof of Concept (PoC) stages (PD-1/VEGF, EGFR/HER3 ADC, SNA spherical small nucleic acids, DKK1 monoclonal antibody, CD20/CD3 bispecific antibody) [2] - Potential for Global Expansion: There is speculation that if Junshi can successfully enter international markets, it may become the next billion-dollar biopharmaceutical company [2]